Article Sidebar

Submitted
Nov 17, 2024
Published
Nov 17, 2024
Download
PDF
Statistic
Read Counter : 14 Download : 10

Main Article Content

Abstract

This study evaluates the anti-hyperlipidemic activity of ethanolic extract from the stem bark of Acacia ferruginea in high-fat diet-induced hyperlipidemic Wistar rats. The experimental model involved administering graded doses of the extract and comparing its effects with a standard reference drug, Atorvastatin. The study demonstrated that the ethanolic extract significantly reduced serum triglycerides, total cholesterol, low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL) levels while increasing high-density lipoprotein (HDL) levels in a dose-dependent manner.  The findings highlight the potential of Acacia ferruginea as a natural therapeutic agent for managing hyperlipidemia and associated cardiovascular risks.

Keywords

Acacia ferruginea Anti-hyperlipidemic activity High-fat diet Lipid profile Ethanolic extract Wistar rats Cardiovascular health Hepatoprotection

Article Details

How to Cite
S. Deepanchakkaravarthi, S. Kameshwaran, & L. Pradeep. (2024). Evaluation Of Anti-Hyperlipidemic Activity Of Ethanolic Extract Of Stem Bark Of Acacia Ferruginea In High Fat Diet-Induced Hyperlipidemic Rats. International Journal of Research in Pharmacology & Pharmacotherapeutics, 13(4), 605-614. Retrieved from https://ijrpp.com/ijrpp/article/view/594
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. 1. Ganong WF. Review of Medical Physiology,22nd ed. New York: McGraw-Hill,2005:303
  2. 2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
  3. 3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [erratum appears in Circulation 2004;110(6):763]. Circulation 2004;110:227–239. [PubMed: 15249516]
  4. 4. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute [erratum appears in Circulation 2006;113(22):e847]. Circulation 2006;113:2363–2372. [PubMed: 16702489]
  5. 5. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007;115:1481–1501. [PubMed: 17309915]
  6. 6. Fletcher B, Berra K, Ades P, et al. Managing abnormal blood lipids: A collaborative approach. Circulation 2005;112: 3184–3209. [PubMed: 16286609]
  7. 7. Menotti A, Lanti M, Nedeljkovic S, Nissinen A, Kafatos A, Kromhout D. The relationship of age, blood pressure, serum cholesterol and smoking habits with the risk of typical and atypical coronary heart disease death in the European cohorts of the Seven Countries Study. Int J Cardiol 2006;106: 157–163. [PubMed: 16321686]
  8. 8. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): A case– control study. Lancet 2008;372:224–233. [PubMed: 18640459]
  9. 9. Rader DJ. Mechanisms of disease: HDL metabolism as a target for novel therapies. Nat Clin Pract Cardiovasc Med 2007;4:102–109. [PubMed: 17245404].
  10. 10. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255– 2267.
  11. 11. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029–1036. [PubMed: 9531248]
  12. 12. Huttunen JK, Manninen V, Manttari M, et al. The Helsinki Heart Study: Central findings and clinical implications. Ann Med 1991;23:155–159. [PubMed: 2069792]
  13. 13. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: Its etiology, effects and treatment. CMAJ 2007;176:1113–1120. [PubMed: 17420495]
  14. 14. Ganong WF. Pathophysiology of Disease: An Introduction to Clinical Medicine, 5th ed. New York: McGraw Hill, 2006
  15. 15. Kasper DL, Braunwald E, Fauci AS, et al., eds. Harrison’s Principles of Internal Medicine, 16th ed. New York, McGraw-Hill, 2005, p. 2289
  16. 16. Breslow JL. Genetic basis of lipoprotein disorders. J Clin Invest 1989;84:373.
  17. 17. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement [erratum appears in Circulation 2005;112(17):e297]. Circulation 2005;112:2735–2752. [PubMed:16157765]
  18. 18. Daniels SR, Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008;122:198–208. [PubMed:18596007]
  19. 19. Trejo-Gutierrez JF, Fletcher G. Impact of exercise on blood lipids and lipoproteins. J Clin Lipidol 2007;1: 175–181. [PubMed: 21291678]
  20. 20. Williams MA, Haskell WL, Ades PA, et al. Resistance exercise in individuals with and without cardiovascular disease: 2007 update: A scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2007;116:572–584. [PubMed: 17638929]
  21. 21. Eckel RH, Borra S, Lichtenstein AH, Yin-Piazza SY, Trans Fat Conference Planning Group. Understanding the complexity of trans fatty acid reduction in the American diet: American Heart Association Trans Fat Conference 2006: Report of the Trans Fat Conference Planning Group. Circulation 2007;115:2231 2246.[PubMed: 17426064]
  22. 22. American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ, et al. Diet and lifestyle recommendations revision 2006: A scientific statement from the American Heart Association Nutrition Committee [erratum appears in Circulation 2006;114(1):e27]. Circulation 2006;114:82–96.
  23. 23. Sacks FM, Lichtenstein A, Van Horn L, et al. Soy protein, isoflavones, and cardiovascular health: An American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006;113:1034–1044. [PubMed: 16418439]
  24. 24. Gidding SS, Dennison BA, Birch LL, et al. Dietary recommendations for children and adolescents: A guide for practitioners: Consensus statement from the American Heart Association [erratum appears in Circulation 2005;112(15):2375]. Circulation 2005;112:2061–2075. [PubMed: 16186441]
  25. 25. McKenney JM. Introduction. Report of the National Lipid Association’s Safety Task Force: The nonstatins. Am J Cardiol 2007;99:1C–58C.
  26. 26. Blank B, Pfeiffer FR, Greenberg CM, Kerwin JF (1963): Thyromimetics. II.The synthesis and hypocholesterolemic activity of some beta-dimethylaminoethyl esters of iodinated thyroalkanoic acids.J Med Chem 6: 560–563.
  27. 27. Friedewald WT, Levy RI, Fredrickson DS (1972): Estimation of the con-centration of low density lipoprotein cholesterol without the use of the preparative ultracentrifuge. Clin Chem 18: 499–502. Szkudelski T, Kandulska K, Okulicz M: Alloxan in vivo does not only exert deleterious effects on pancreatic B cells. Physiol Res 1998;47:343.
  28. 28. Kliber A, Szkudelski T, Chichlowska J. Alloxan stimulation and subsequent inhibition of insulin release from in situ perfuse d rat pancreas. J Physiol Pharmacol 1996;47:321-8.
  29. 29. Lenzen S, Munday R. Thiol – group reactivity, hydrophilicity and stability of alloxan, its reduction products and its N -methyl derivatives and a comparison with ninhydrin. Biochem Pharmacol 1991;42:1385-91.
  30. 30. Zhang H, Zdolsek JM, Brunk UT. Alloxan cytotoxicity involves lysosomal damage. APMIS 1992;100:309-16.
  31. 31. Munday R. Dialuric acid autoxidation. Effects of transition metals on the reaction rate and on the generation of reactive oxygen species. Biochem Pharmacol 1988;37:409-13.
  32. 32. Ebelt H, Peschke D, Bromme HJ, Morke W, Blume R, Peschke E: Influence of melatonin on free radical –induced changes in rat pancreatic beta cells in vitro. J Pineal Res 2000;28: 65 -72.
  33. 33. Szkudelski T. The Mechanism of Alloxan and Streptozotocin Action in B Cells of the R at Pancreas Physiol Res 2001;50:536 -46.
  34. 34. Gerhard Vogel H. Drug Discovery and evaluation-pharmacological assays, 2 nd ed. NewYork: Spinger Verlag Berlins Heidelberg Publication;2002:947-1002.
  35. 35. Akare S.C., Sahare A.Y., Shende M.A., Bondre A.V. & Wanjari A.D., Hepatoprotective activity of acacia ferruginea dc. leaves against carbon tetrachloride induced liver damage in rats. Interna. Journal of Pharm Tech Research.2009;1(3):962-965.
  36. 36. M. Madhavi, S. Kiran and D. Ramesh, Evaluation of Antidiabetic, Antihyperlipidemic and Antioxidant Activities of Acacia leucophloea in Streptozotocin-Nicotinamide Induced Type II Diabetic in Rats, Global Journal of Pharmacology. 2014; 8 (1): 64-72.
  37. 37. Gehan A. Hegazy, Amina M. Alnoury, Hoda G. Gad. The role of Acacia Arabica extract as an antidiabetic, antihyperlipidemic, and antioxidant in streptozotocin- induced diabetic rats. Saudi Med J 2013; Vol. 34 (7): 727-733.
  38. 38. Waheeb dakhelallah mohammad alharbi And aisha azmat. Hypoglycemic and hypocholesterolemic effects Of Acacia tortilis(fabaceae) growing in makkah. Pakistan Journal of Pharmacology. 2011;28(1):1-8.
  39. 39. Jhuma Deb, Gouri Kumar Dash. Pharmacognostical studies on stem bark of Acacia ferruginea DC. Der Pharmacia Lettre, 2014; 6 (3):61-66.
  40. 40. Khan A, Sohaib M, Ullah R, Hussain I, Niaz S, Malak N, de la Fuente J, Khan A, Aguilar-Marcelino L, Alanazi AD, Ben Said M. Structure-based in silico design and in vitro acaricidal activity assessment of Acacia nilotica and Psidium guajava extracts against Sarcoptes scabiei var. cuniculi. Parasitology Research. 2022 Oct;121(10):2901-15.
  41. 41. Jeevitha M, Ravi PV, Subramaniyam V, Pichumani M, Sripathi SK. Exploring the phyto-and physicochemical evaluation, fluorescence characteristics, and antioxidant activities of Acacia ferruginea Dc: an endangered medicinal plant. Future Journal of Pharmaceutical Sciences. 2021 Dec;7:1-7.
  42. 42. Khalaf SS, Shalaby OA, Hassan AR, El-Kherbetawy MK, Mehanna ET. Acacia nilotica stem bark extract ameliorates obesity, hyperlipidemia, and insulin resistance in a rat model of high fat diet-induced obesity. Journal of traditional and complementary medicine. 2023 Jul 1;13(4):397-407